Please Wait
Applying Filters...
menu
    • menu
    Aspen API. More than just an API™

    Virtual Booth

    Contact Supplier

    Sharp is a leader in commercial packaging, clinical services, and sterile manufacturing.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    An Enquiry

    Menu

    Exatecan

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    DIGITAL CONTENT

    MARKET PLACE

    PharmaCompass
    $ API Ref.Price (USD/KG) : 77,610Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    FDA Clears Avacta's IND Application for AVA6103 (FAP-Exatecan)
    FDA Clears Avacta's IND Application for AVA6103 (FAP-Exatecan)

    21 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/21/3222755/0/en/Avacta-Announces-U-S-Food-and-Drug-Administration-Clearance-of-the-Investigational-New-Drug-IND-Application-for-the-Second-pre-CISION-Medicine-FAP-Exatecan-AVA6103.html

    GLOBENEWSWIRE
    21 Jan 2026
    Share Share
    FDA Grants Breakthrough Designation to Lilly's Sofetabart
    FDA Grants Breakthrough Designation to Lilly's Sofetabart

    20 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/lillys-sofetabart-mipitecan-receives-us-fdas-breakthrough-therapy-designation-for-the-treatment-of-certain-patients-with-platinum-resistant-ovarian-cancer-302665319.html

    PR NEWSWIRE
    20 Jan 2026
    Share Share
    Sutro Bio Doses First Patients In STRO-004, Phase 1 Trial
    Sutro Bio Doses First Patients In STRO-004, Phase 1 Trial

    03 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/03/3198799/0/en/Sutro-Biopharma-Announces-First-Cohort-of-Patients-Dosed-in-Phase-1-Trial-of-STRO-004-a-Next-Generation-Tissue-Factor-ADC-in-TF-Expressing-Solid-Tumors.html

    GLOBENEWSWIRE
    03 Dec 2025
    Share Share
    Kivu Bioscience Shows Strong Anti-Tumor Activity Of KIVU-107
    Kivu Bioscience Shows Strong Anti-Tumor Activity Of KIVU-107

    20 Oct 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-10-20/kivu-bioscience-presents-preclinical-data-for-kivu-107-demonstrating-potent-and-durable-anti-tumor-a

    PHARMIWEB
    20 Oct 2025
    Share Share
    Sutro Bio Initiates Restructuring To Extend Cash Runway
    Sutro Bio Initiates Restructuring To Extend Cash Runway

    29 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/29/3158177/0/en/Sutro-Biopharma-Announces-Operational-Restructuring-Intended-to-Extend-Cash-Runway-through-Key-Milestones.html

    GLOBENEWSWIRE
    29 Sep 2025
    Share Share
    Sutro Biopharma to Present Next-Gen Exatecan at AACR 2025
    Sutro Biopharma to Present Next-Gen Exatecan at AACR 2025

    28 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/28/3069634/0/en/Sutro-Biopharma-to-Highlight-its-Next-Generation-Exatecan-and-Dual-Payload-ADC-Programs-in-Presentations-at-AACR-2025.html

    GLOBENEWSWIRE
    28 Apr 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.